Does Harvard Pilgrim Health Care Cover Forteo (Teriparatide)?

What Is Forteo and Why Is It Prescribed?

Forteo (teriparatide) is a recombinant human parathyroid hormone 1-34 fragment that stimulates new bone formation rather than simply slowing bone loss. The FDA approved it in November 2002 for postmenopausal women with osteoporosis at high fracture risk, men with primary or hypogonadal osteoporosis, and men and women with glucocorticoid-induced osteoporosis [1]. It is self-administered as a 20 mcg subcutaneous injection once daily from a prefilled pen, and FDA labeling caps cumulative lifetime use at 24 months [1].

Teriparatide's anabolic mechanism sets it apart from antiresorptive agents such as alendronate, zoledronic acid, or denosumab. The key fracture trial by Neer et al. (N=1,637 postmenopausal women) showed that teriparatide 20 mcg/day reduced new vertebral fractures by 65% versus placebo (relative risk 0.35 to 95% CI 0.22-0.55, P<0.001) and non-vertebral fragility fractures by 53% after a median 21 months [2]. Those numbers explain why guidelines reserve it for patients at the highest fracture risk rather than using it as a first-line agent.

The American Association of Clinical Endocrinology (AACE) 2020 clinical practice guidelines classify teriparatide as a first-choice anabolic therapy for patients with very high fracture risk, defined as a prior hip or vertebral fracture, T-score at or below -3.0, or multiple fractures [3]. The Endocrine Society similarly recommends anabolic therapy before antiresorptive therapy in patients at imminent fracture risk [4]. These guideline positions directly shape the medical necessity criteria insurers write into their prior-authorization policies.

Because teriparatide costs roughly $3,000-$4,000 per month at list price, every major commercial insurer, including Harvard Pilgrim Health Care, places it on a specialty tier and requires prior authorization before dispensing [5].

Does Harvard Pilgrim Health Care Cover Forteo?

Harvard Pilgrim Health Care does cover Forteo, but coverage is not automatic. Prior authorization approval is required across its commercial HMO, PPO, and POS plans as well as its Medicare Advantage products. Harvard Pilgrim is a subsidiary of Point32Health, which administers pharmacy benefits using a specialty formulary structured around clinical criteria aligned with published osteoporosis guidelines [6].

The short answer: yes, Forteo appears on Harvard Pilgrim's specialty formulary, but a prescriber must submit a prior-authorization request that satisfies specific clinical criteria before the plan will pay.

Harvard Pilgrim's publicly available formulary documents and coverage policies indicate that anabolic bone agents, including teriparatide, require demonstration of all of the following before approval is granted:

1. A confirmed diagnosis of osteoporosis (T-score at or below -2.5 on dual-energy X-ray absorptiometry, or a fragility fracture history consistent with osteoporosis).
2. Documentation that the member has experienced an inadequate response to, or has a contraindication or intolerance to, at least one bisphosphonate (typically oral alendronate or risedronate, or intravenous zoledronic acid).
3. Prescriber attestation that the patient is at high or very high fracture risk, often supported by a FRAX score above the intervention threshold recommended by the National Osteoporosis Foundation [7].
4. Confirmation that the member does not have conditions that represent absolute contraindications in FDA labeling, including hypercalcemia, skeletal malignancy, prior radiation therapy involving the skeleton, Paget's disease of bone, or unexplained elevation of alkaline phosphatase [1].

Approvals are typically issued for an initial 6-month period, with renewal requiring clinical documentation of continued need and ongoing response. The 24-month lifetime cumulative limit in FDA labeling is enforced as a hard stop regardless of clinical benefit after that point.

How to Get Harvard Pilgrim Prior Authorization for Forteo

The prior-authorization process has several discrete steps, each with its own documentation requirement.

Step 1: Prescriber initiates the PA request. The ordering endocrinologist, rheumatologist, or primary care physician submits a PA request through Harvard Pilgrim's online provider portal or via fax to the pharmacy benefit management unit. Harvard Pilgrim uses CVS Caremark as its pharmacy benefit manager for most commercial plans, so the PA form is typically the CVS Caremark specialty PA form for osteoporosis anabolic agents [6].

Step 2: Submit clinical documentation. Required documents generally include the most recent dual-energy X-ray absorptiometry (DXA) report with T-scores at the lumbar spine and hip, a fracture history summary, documentation of prior bisphosphonate use (drug name, dose, duration, and reason for discontinuation or inadequate response), and the most recent FRAX score if available. The World Health Organization developed the FRAX tool specifically to estimate 10-year fracture probability, and a major osteoporotic fracture probability above 20% or a hip fracture probability above 3% triggers treatment in most U.S. guidelines [7].

Step 3: Harvard Pilgrim clinical review. A pharmacist or physician reviewer at Harvard Pilgrim or CVS Caremark evaluates the submission against the plan's coverage criteria within the timeframe mandated by Massachusetts insurance regulations (typically 72 hours for standard review, 24 hours for urgent requests).

Step 4: Approval, denial, or request for additional information. If approved, the authorization is valid for 6 months in most cases. If denied, the member and prescriber receive a written denial with the specific clinical reason and instructions for filing an appeal.

Step 5: Appeals. A first-level internal appeal must be filed within 180 days of the denial in most Harvard Pilgrim plans. If the internal appeal is denied, the member may request an external independent medical review under Massachusetts General Law Chapter 176O, which requires the plan to abide by the independent reviewer's determination [8].

Prescribers who include a detailed letter of medical necessity referencing the AACE 2020 guidelines [3] and citing the Neer et al. fracture reduction data [2] typically have stronger appeals outcomes than those who submit only checkboxes on a standard form.

Clinical Evidence Supporting Forteo Coverage Decisions

Insurance coverage criteria are built on the same clinical evidence that guidelines cite, so understanding the trial data strengthens the case for medical necessity.

The Neer et al. fracture trial (N=1,637) remains the foundational study. Participants were postmenopausal women with at least one prior vertebral fracture who received teriparatide 20 mcg/day or placebo for a median of 21 months. The 20 mcg dose reduced new vertebral fractures by 65% and increased lumbar spine bone mineral density by 9.7% versus a 1.1% increase with placebo [2]. Harvard Pilgrim's clinical criteria for fracture history align directly with the enrollment criteria of that trial.

The VERO trial (N=1,360) compared teriparatide 20 mcg/day with risedronate 35 mg/week in postmenopausal women with severe osteoporosis and at least two moderate or one severe vertebral fracture. At 24 months, teriparatide reduced new vertebral fractures by 56% compared with risedronate (odds ratio 0.44 to 95% CI 0.29-0.68, P<0.001), and reduced clinical fractures by 52% [9]. This head-to-head superiority over a bisphosphonate is one reason guidelines recommend anabolic-first sequencing in very high-risk patients and why bisphosphonate failure criteria in PA forms exist.

Bone mineral density gains are durable only when followed by antiresorptive therapy after teriparatide is stopped. The DATA-Switch trial (N=94) found that women who transitioned from teriparatide to denosumab gained further bone density at all skeletal sites, whereas those who transitioned to placebo lost the gains made during teriparatide treatment [10]. This evidence supports the clinical sequencing that Harvard Pilgrim's PA reviewers expect prescribers to plan for at the time of initial authorization.

For glucocorticoid-induced osteoporosis, a randomized trial by Saag et al. (N=428) comparing teriparatide with alendronate in patients receiving at least 5 mg/day of prednisone equivalent for 3 or more months found that teriparatide reduced new vertebral fractures by 90% relative to alendronate over 36 months (3.7% vs. 0.6% incidence, P=0.004) [11]. Harvard Pilgrim's PA criteria specifically accommodate glucocorticoid-induced osteoporosis as a separate pathway, often without the bisphosphonate-failure requirement if the prescriber documents the indication clearly and references this trial.

How Much Does Forteo Cost With Harvard Pilgrim Coverage?

Cost-sharing on a specialty tier varies by plan design. Under Harvard Pilgrim commercial plans, specialty-tier cost-sharing commonly ranges from 20%-33% coinsurance or a fixed copay between $100 and $300 per 28-day supply after the deductible is met [5]. Given the list price of approximately $3,000-$4,000 per month, even 20% coinsurance produces a $600-$800 monthly out-of-pocket obligation before any assistance programs are applied.

Harvard Pilgrim Medicare Advantage plans follow Part D formulary rules. Teriparatide falls into a specialty tier under Part D, where cost-sharing is capped in the catastrophic phase under the Inflation Reduction Act of 2022 [12]. For 2025, the Medicare Part D out-of-pocket cap is $2,000 per year, which can substantially reduce costs for seniors who use teriparatide for the full 24-month treatment course [12].

Eli Lilly offers the Forteo Savings Card for commercially insured patients who meet income thresholds, which may reduce cost-sharing to as low as $25 per month for eligible patients. Patients who lack insurance or whose insurance denies coverage may qualify for the Lilly Cares Foundation Patient Assistance Program, which provides Forteo at no cost to patients meeting income eligibility criteria [13]. The prescriber's office typically initiates enrollment.

Members should also confirm whether their specific Harvard Pilgrim plan uses a closed or open formulary, because some employer-sponsored self-insured plans administered by Harvard Pilgrim may have custom formularies that differ from the standard benefit design. A direct call to the member services number on the back of the insurance card, with the drug's NDC number in hand, produces the most accurate tier and cost-sharing information.

Forteo Versus Alternatives: What Harvard Pilgrim Also Covers

Understanding the alternatives helps patients and prescribers anticipate coverage decisions, since Harvard Pilgrim's PA criteria for Forteo often require documented failure of at least one alternative.

Bisphosphonates (alendronate, risedronate, zoledronic acid, ibandronate) are generic first-line agents placed on Tier 1 or Tier 2, typically with $0-$20 copays and no prior authorization required for most plans [5]. Alendronate 70 mg/week reduced vertebral fractures by 47% over 3 years in the FIT trial (N=2,027) [14], making it the standard first step before anabolic therapy is considered.

Denosumab (Prolia) is a RANK-L inhibitor administered as a 60 mg subcutaneous injection every 6 months. It sits on Tier 3 or specialty tier at Harvard Pilgrim and requires prior authorization, though criteria are less stringent than for teriparatide. The FREEDOM trial (N=7,868) found denosumab reduced new vertebral fractures by 68% at 36 months versus placebo [15]. Some Harvard Pilgrim plans require denosumab failure before approving Forteo; others accept documented bisphosphonate failure alone.

Abaloparatide (Tymlos) is the other FDA-approved anabolic agent. The ACTIVE trial (N=2,463) showed abaloparatide 80 mcg/day reduced new vertebral fractures by 86% versus placebo over 18 months [16]. Harvard Pilgrim covers abaloparatide under similar PA criteria as teriparatide. Some plans may prefer one over the other based on net pricing negotiated with manufacturers, so checking the formulary for the specific plan year is necessary.

Romosozumab (Evenity) is a sclerostin inhibitor given as two 105 mg subcutaneous injections monthly for 12 months. The ARCH trial (N=4,093) found romosozumab followed by alendronate reduced new vertebral fractures by 48% versus alendronate alone at 24 months [17]. Harvard Pilgrim covers romosozumab on the specialty tier with PA required, and it carries an FDA boxed warning for cardiovascular events, which restricts use in patients with prior myocardial infarction or stroke [17].

What to Do If Harvard Pilgrim Denies Forteo Coverage

A denial is not a final answer. Three practical paths exist after a denial.

File an internal appeal with supporting clinical evidence. The appeal letter should directly cite the patient's T-score, fracture history, FRAX score, prior bisphosphonate trial documentation, and the applicable AACE 2020 guideline recommendation [3]. Quoting the VERO trial data showing teriparatide's superiority over risedronate [9] adds objective trial evidence to the clinical narrative.

Request an expedited external review. Under Massachusetts law (Chapter 176O) and the ACA's external review provisions, members have the right to an independent review of denied claims for experimental or non-covered services [8]. Teriparatide is not experimental, so denials based on medical necessity criteria are reviewable. Independent reviewers overturn insurer denials at meaningful rates when the clinical documentation is thorough.

Use manufacturer assistance programs while the appeal proceeds. Eli Lilly's Lilly Cares Foundation can provide Forteo during the gap period [13]. The prescriber's office can submit the application, and approval often comes within 2-3 weeks for qualifying patients.

Explore biosimilar or step-edit options. As of 2025, no FDA-approved generic teriparatide is available in the United States, but Eli Lilly's own authorized generic, launched in some markets, may appear on some formularies at a lower tier. Confirming with Harvard Pilgrim member services whether an authorized generic is listed separately is worth the phone call [1].

Bone Health Monitoring Requirements During Forteo Treatment

Harvard Pilgrim's PA renewal criteria typically require evidence of ongoing monitoring, and prescribers who document this proactively reduce the chance of a mid-treatment denial.

The National Osteoporosis Foundation recommends DXA scanning at baseline and after 1-2 years of anabolic therapy to assess response [7]. A meaningful response is generally defined as a statistically significant increase in lumbar spine BMD above the least significant change threshold for the specific DXA machine used. The International Society for Clinical Densitometry defines the least significant change as approximately 2.8 times the precision error of the DXA scanner [18].

Serum calcium should be checked at baseline and periodically during treatment, given teriparatide's stimulation of intestinal calcium absorption and its potential to cause transient hypercalcemia [1]. The FDA label recommends checking calcium before initiating therapy and monitoring for symptoms of hypercalcemia during treatment. Alkaline phosphatase, a marker of bone formation, typically rises during teriparatide treatment and represents an expected pharmacodynamic response rather than a safety signal, provided other causes of elevated alkaline phosphatase have been excluded [2].

Urinary calcium excretion monitoring is relevant in patients with a history of nephrolithiasis, since teriparatide increases urinary calcium and is relatively contraindicated in patients with active nephrolithiasis [1].

Vitamin D status should be confirmed at baseline and maintained in the sufficient range (serum 25-hydroxyvitamin D at or above 30 ng/mL) throughout treatment, because inadequate vitamin D blunts teriparatide's anabolic effect on bone. The Endocrine Society's clinical practice guideline on vitamin D recommends 1,500-2 to 000 IU/day of supplemental vitamin D3 for most adults with confirmed insufficiency [19].

Transitioning Off Forteo: What Happens After 24 Months

The 24-month lifetime limit on teriparatide is not merely a coverage rule. It reflects FDA labeling based on an animal carcinogenicity study in which high-dose, long-duration exposure caused osteosarcomas in rats [1]. No human cases of osteosarcoma attributable to teriparatide at therapeutic doses have been confirmed, but the FDA cap remains in place, and Harvard Pilgrim enforces it as a hard stop on PA renewal.

After 24 months of teriparatide, antiresorptive consolidation therapy is necessary to preserve gains. The DATA-Switch trial demonstrated that women who transitioned to denosumab after teriparatide continued to gain bone density at all sites over the subsequent 24 months [10]. Women who received no therapy after teriparatide lost bone at the hip within 6-12 months.

Harvard Pilgrim covers denosumab (Prolia) and oral bisphosphonates for post-anabolic consolidation, and PA requirements for denosumab are generally less stringent than for teriparatide given the established evidence base [15]. Prescribers planning the teriparatide treatment course should document the planned consolidation strategy in the medical record from the outset, as this demonstrates adherence to guideline-recommended sequencing and may support continued coverage decisions.

Zoledronic acid 5 mg intravenously once yearly is an alternative consolidation option, particularly for patients who cannot tolerate oral bisphosphonates. A clinical trial by Black et al. (N=1,256) showed that a single infusion of zoledronic acid given 12 months after teriparatide was discontinued maintained lumbar spine BMD and was superior to placebo consolidation at preventing BMD loss [20].